Research Article

The Impact of Chronic Kidney Disease and Short-Term Treatment with Rosiglitazone on Plasma Cell-Free DNA Levels

Amanda L. McGuire,1,2 Nadia Urosevic,3 Doris T. Chan,4 Gursharan Dogra,4 Timothy J. J. Inglis,3,5 and Aron Chakera1,2,4,6

1 School of Medicine and Pharmacology, University of Western Australia, Nedlands, WA, Australia
2 Harry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands, WA, Australia
3 Department of Microbiology, PathWest Laboratory Medicine WA, Nedlands, WA, Australia
4 Department of Renal Medicine, Sir Charles Gairdner Hospital, Nedlands, WA, Australia
5 School of Pathology and Laboratory Medicine, University of Western Australia, Nedlands, WA, Australia
6 Translational Renal Research Group, Harry Perkins Institute of Medical Research, 5th Floor QQ Block, QEII Medical Centre, 6 Verdun Street, Nedlands 6009, Australia

Correspondence should be addressed to Aron Chakera; aron.chakera@uwa.edu.au

Received 2 May 2014; Revised 11 August 2014; Accepted 20 August 2014; Published 13 October 2014

Academic Editor: Sharon Cresci

Copyright © 2014 Amanda L. McGuire et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Patients with chronic kidney disease (CKD) are at increased risk of cardiovascular disease. Circulating free nucleic acids, known as cell-free DNA (cfDNA), have been proposed as a novel biomarker of cardiovascular risk [3], with elevated levels also reported in a variety of inflammatory states, including treatment with haemodialysis [4–11]. The development of noninvasive measures to quantify this risk and therapies that may reduce this risk are therefore of significant clinical interest. Several small case series have suggested that cfDNA levels are not affected by renal dysfunction; however, the effect of different degrees of renal impairment has not been systematically studied nor has the impact of anti-inflammatory agents on cfDNA levels. As cfDNA levels may provide a way to noninvasively monitor disease activity and to predict clinical outcomes [10], determining whether cfDNA levels reflect the elevated cardiovascular risk and endothelial dysfunction that occurs with CKD is of clinical relevance.

As chronic kidney disease (CKD) is considered a proinflammatory state [12,13], we hypothesised that cfDNA levels would be elevated in patients with renal impairment and

1. Introduction

Patients with renal impairment have an elevated risk of cardiovascular disease, which increases as renal function declines [1, 2]. Recently, the presence of free nucleic acids in the peripheral circulation, referred to as cell-free DNA (cfDNA), has been proposed as a novel biomarker of cardiovascular risk [3], with elevated levels also reported in a variety of inflammatory states, including treatment with haemodialysis [4–11]. The development of noninvasive measures to quantify this risk and therapies that may reduce this risk are therefore of significant clinical interest. Several small case series have suggested that cfDNA levels are not affected by renal dysfunction; however, the effect of different degrees of renal impairment has not been systematically studied nor has the impact of anti-inflammatory agents on cfDNA levels. As cfDNA levels may provide a way to noninvasively monitor disease activity and to predict clinical outcomes [10], determining whether cfDNA levels reflect the elevated cardiovascular risk and endothelial dysfunction that occurs with CKD is of clinical relevance.

As chronic kidney disease (CKD) is considered a proinflammatory state [12,13], we hypothesised that cfDNA levels would be elevated in patients with renal impairment and
that treatments that decreased endothelial dysfunction would reduce cfDNA levels. To answer these questions, we measured plasma cfDNA levels in 127 patients with a wide range of renal impairment (CKD stages 2–5) who participated in two randomized controlled trials that investigated vascular function and inflammation in patients with CKD [14, 15]. In addition to quantifying the total amount of cfDNA, as apoptotic cfDNA may have specific effects on endothelial cells, in a subset of patients the proportion of apoptotic cfDNA (fragments sizes of 160–200 bp) was assessed [16]. Next, to determine if there was a link between cfDNA levels and endothelial dysfunction and inflammation in CKD [17–20], we measured concentrations of cfDNA and inflammatory cytokines in 70 patients treated with either placebo or the peroxisome proliferator-activated receptor gamma (PPARγ) agonist rosiglitazone for 8 weeks [15].

2. Materials and Methods

2.1. Patient Cohorts. Clinical samples were obtained from participants in two trials referred to internally as REVERT [15] and SAFIRE [14]. REVERT was a randomized, double-blind placebo-controlled study comparing 8-week treatment with rosiglitazone 4 mg daily in 70 patients with stages 3–4 CKD. Plasma samples were available for all 70 subjects at baseline and week 8 (140 samples in total). SAFIRE was a randomized, double-blind placebo-controlled parallel group study comparing atorvastatin, 40 mg daily (n = 31), gemfibrozil, 600 mg twice daily (n = 27), and placebo (n = 32) for 6 weeks in patients with stages 3–5 CKD. (Following screening, several patients in both studies had baseline eGFRs between 60 and 90 mL/min/1.73 m² and were therefore classified as CKD stage 2.) Plasma samples were available for 19 patients in the atorvastatin group, 17 from the gemfibrozil group, and 21 who received placebo at baseline and week 6 (114 samples in total). 26% of the SAFIRE subjects were on haemodialysis and 14% on peritoneal dialysis. This study was approved by the Ethics Committees of Royal Perth and Sir Charles Gairdner Hospitals. Written informed consent was obtained from all participants and research was conducted in accordance with the Declaration of Helsinki.

2.2. Plasma cfDNA Isolation. Cell-free DNA was isolated using a QIAamp DNA Blood Mini Kit (Qiagen) with modifications as described previously [21]. Plasma samples were obtained from either citrate or EDTA collections, which with our protocol yield equivalent cfDNA levels (see Supplementary Figure 1 in Supplementary Material available online at http://dx.doi.org/10.1155/2014/643189). Briefly, plasma samples were thawed at room temperature (RT), inverted to mix, and centrifuged at maximum speed for 10 minutes at 4°C in a microcentrifuge. 200 μL aliquots of plasma were removed for cfDNA isolation and incubated with RNase A and Proteinase K before binding of cfDNA to the supplied columns. Two wash steps were performed; then cfDNA was eluted with 50 μL of nuclease-free water (incubated for 5 minutes at room temperature before centrifugation), and the eluate passed through the membrane a second time to maximise recovery. cfDNA was stored at 4°C for up to a month or at −20°C for extended storage.

2.3. cfDNA Quantification. cfDNA was quantified using the Qubit dsDNA HS Assay Kit (Life Technologies, CA) according to the manufacturer’s protocol. cfDNA samples (10 μL) were added to Qubit Working Solution (190 μL), vortexed for 5 seconds, and incubated at RT for 2 minutes. A Qubit 2.0 Fluorometer (Life Technologies, CA) was used to calculate the dsDNA concentration.

2.4. cfDNA Analysis. To determine the amount of apoptotic cfDNA present, 1 μL aliquots of cfDNA were analysed on Agilent DNA 12,000 chips using an Agilent 2100 Bioanalyzer (Agilent Technologies, California, USA) according to the manufacturer’s instructions. All sample wells contained two internal markers of known size (50 bp and 17 kb) and DNA ladder.

2.5. Cytokine Measurements. The cytokines IL-1β, IL-6, IL-8, IL-10, and TNFα were quantified using the Milliplex MAP High Sensitivity Human Cytokine magnetic bead panel (EMD Millipore Corp., St. Charles, MO, USA) with plates read on a Luminex 200 system using xPonent software, version 3.1 (Luminex Corporation, Austin, TX, USA). 50 μL of plasma was analysed per well, and all samples were assayed in duplicate as per the manufacturer’s recommendation. Normalisation of data from different assay plates was performed by Merck Millipore (Frenchs Forest, NSW, Australia). Data for IL-10 was subsequently excluded from analyses due to excessive variance from the reported sensitivity and performance of the IL-10 assay. To confirm the accuracy of the Luminex system, IL-6 results were compared with those obtained using a quantitative enzyme immunoassay (Quantikine HS; R&D Systems Inc., Minneapolis, MN) and found to be highly correlated (P < 0.0001). von Willebrand factor (vWF) activity was measured with the AT-A-Liatest vWF kit (Diagnostica Stago, Parsippany, NJ) and Diagnostica Stago STAR-automated coagulation analyser. High sensitivity C-reactive protein (hsCRP) levels were determined with an immunonephelometric method (Dade Behring Marburg GmbH, Marburg, Germany).

2.6. Statistical Analysis. Statistical analyses were performed using Prism 6 (Graphpad Software, La Jolla, CA, USA). Normality was assessed using the D’Agostino and Pearson omnibus test. Corrections for multiple comparisons were performed using Dunn’s test. Statistical significance was defined as P < 0.05.

3. Results

Baseline cfDNA levels from REVERT and SAFIRE were grouped by CKD status (stages 2–5) and the mean, median, and interquartile ranges calculated. One hundred and twenty-seven samples had baseline cfDNA results available; one sample (from a patient with CKD stage 5) was excluded from further analyses, as cfDNA levels were more
than 10-fold higher than other values. Median cfDNA levels for each CKD stage were 2 (8.4 ng/mL), 3 (7.9 ng/mL), 4 (6.8 ng/mL), and 5 (7.7 ng/mL) (Figure 1(a)). There were no significant differences in cfDNA levels between any of the CKD stages ($P = 0.5$). As separating patients by CKD stage could reduce the ability to detect a more subtle relationship between cfDNA and renal function, the association between cfDNA levels and individual patient’s estimated glomerular filtration rates (eGFR) was explored. No correlation between cfDNA and eGFR levels was evident ($P = 0.87$) (Figure 1(b)).

cfDNA can be derived from necrotic or apoptotic cells, which may reflect the underlying processes leading to its production and influence its biological properties [16]. To determine the relative proportion of apoptotic versus necrotic cfDNA in our patients, a subset of 12 plasma samples from both the SAFIRE and REVERT cohorts (including patients whose cfDNA levels remained constant, increased, or decreased at follow-up) were analysed on Agilent DNA 12,000 chips. No apoptotic DNA fragments were present in any of the samples tested (Supplementary Figure 2).

Haemodialysis is an intermittent therapy, which can lead to the release of inflammatory mediators, and has been shown to cause an increase in cfDNA levels [11]. Whether similar changes occur in patients receiving peritoneal dialysis (a continuous therapy) is unclear. To answer this question we measured cfDNA levels in 57 patients from the SAFIRE cohort. All samples from haemodialysis patients were collected prior to treatment. There was no difference in baseline cfDNA levels between subjects undergoing haemodialysis (average: 9.0 ng/mL, median: 7.6 ng/mL) or peritoneal dialysis (average: 11.1 ng/mL, median: 9.2 ng/mL) or those individuals not on dialysis (average: 9.8 ng/mL, median: 9.6 ng/mL) ($P = 0.6$) (Figure 2).

The PPARγ agonist rosiglitazone has anti-inflammatory properties, which might influence the generation of cfDNA providing a link between cfDNA, inflammation, and vascular dysfunction in CKD. Therefore, we next compared cfDNA levels at baseline and following 8-week treatment with either placebo or rosiglitazone. No difference in cfDNA levels from baseline was detected in either group ($P = 0.7864$ and $P = 0.1082$ for placebo and rosiglitazone, resp.; see Figure 3). However, on follow-up patients randomized to rosiglitazone were significantly more likely to show a decrease in cfDNA levels (Figure 3(c); $P = 0.046$).

To further assess whether there is a relationship between cfDNA levels, inflammation, and CKD, concentrations of
cytokines linked to inflammation and endothelial dysfunction (IL-1β, IL-6, IL-8, TNFα, hsCRP, and vWF) were compared with levels of cfDNA in all patients from the REVERT cohort. For IL-1β, 56 of the 140 samples (40%) had at least one data point of ≤0.14 pg/mL, which was the limit of detection for this assay. For IL-6, 7 of the 140 samples (5%) had at least one data point of ≤0.14 pg/mL, which was the limit of detection for this assay. All data points for IL-8, TNFα, hsCRP, and vWF had detectable levels of the respective cytokines. Results stratified by CKD stage are shown in Table 1. No relationship between cfDNA and levels of IL-1β, IL-6, IL-8, or TNFα was identified (P > 0.1 for all cytokines) (Figures 4(a)–4(d)). However, cfDNA levels were correlated to levels of hsCRP (P = 0.0497) and vWF (P = 0.0005), which have previously been shown to reflect endothelial dysfunction and associate with elevated cardiovascular risk (Figures 4(e) and 4(f)) [15, 22, 23].

4. Discussion

We report the largest study to date analysing the effect of renal impairment on circulating cfDNA levels and demonstrate that, even in the presence of advanced kidney disease, levels of cfDNA are equivalent to those reported in healthy controls and that apoptotic cfDNA fragments are not present. Eight-week treatment with the peroxisome proliferator-activated receptor (PPAR) agonist rosiglitazone, an agent which has been demonstrated to reduce inflammation and endothelial dysfunction in patients with CKD [15], was associated with an increased likelihood of a reduction in cfDNA levels.

Figure 3: Changes in cfDNA levels. cfDNA levels were measured at baseline and following 8-week treatment with either placebo (a) or rosiglitazone (b). There were no differences between levels at baseline or follow-up in either group (P = 0.79 for placebo and P = 0.11 for rosiglitazone). However, the proportion of patients who had a decrease in their cfDNA levels over the course of the trial was significantly higher in the rosiglitazone-treated group (P = 0.046), shown in (c) as the filled area.
compared to placebo, but the absolute changes were not statistically significant. cfDNA levels correlated with markers of endothelial dysfunction (hsCRP $P = 0.0497$) and vWF ($P = 0.0005$) but not with proinflammatory cytokines in patients with CKD.

Previous studies in patients with end stage kidney disease have shown that cfDNA levels are increased within a few minutes of commencing haemodialysis but that baseline levels are generally equivalent to those found in healthy controls [11, 24]. However, a wide variation in normal ranges has been
Table 1: Baseline characteristics of the study population by CKD stage.

| CKD stage | Median (SD) | Median (SD) | Median (SD) | Median (SD) |
|-----------|-------------|-------------|-------------|-------------|
| cfDNA (ng/mL) | 8.4 (2.80) | 7.9 (3.87) | 6.8 (3.05) | 7.7 (4.86) |
| hsCRP (mg/L) | 1.28 (2.38) | 1.79 (2.25) | 1.58 (1.85) | 1.14 (1.66) |
| vWF (%) | 126 (26.5) | 135 (35.6) | 138.5 (27.9) | 129 (22.4) |
| IL-1β (pg/mL) | 0.21 (2.3) | 0.15 (0.78) | 0.16 (0.79) | 0.17 (0.55) |
| IL-6 (pg/mL) | 1.57 (3.8) | 1.3 (5.2) | 1.7 (2.2) | 1.52 (3.7) |
| IL-8 (pg/mL) | 2.16 (3.7) | 2.66 (5.1) | 2.94 (4.3) | 2.91 (6.01) |
| TNFα (pg/mL) | 2.30 (11.3) | 5.40 (8.5) | 4.66 (9.64) | 5.40 (11.7) |

reported, and comparison between studies is problematic as results of cfDNA assays are highly dependent upon sample collection and processing methods [25, 26]. Using a validated protocol for cfDNA isolation and quantification [21], we analysed cfDNA levels in patients with moderate to severe renal impairment, including patients requiring dialysis. Consistent with previous data, cfDNA levels in patients with CKD stages 2–5, including dialysis dependent patients, were equivalent to those reported for healthy controls [27–30] and no association between eGFR and cfDNA concentrations was detected (Figure 1(b)). In addition, apoptotic DNA fragments were not present, suggesting that the elevated cardiovascular risk associated with CKD is not driven by processes that drive apoptosis or that the amount of apoptosis is insufficient to overwhelm clearance mechanisms [24, 31].

Endothelial dysfunction is an early finding in atherosclerosis and is strongly associated with inflammation and insulin resistance [32, 33]. PPAR agonists are insulin-sensitizing agents marketed for the treatment of type 2 diabetes mellitus that can improve endothelial function and inhibit the development of atherosclerosis [34–36]. Although enthusiasm for their use diminished following publication of a meta-analysis suggesting an increased risk of myocardial infarction in patients treated with rosiglitazone [37], subsequent studies have not supported this finding [38, 39], leading to a resurgence in interest in these agents. In the REVERT trial, short-term rosiglitazone therapy significantly lowered insulin resistance, high sensitivity C-reactive protein (hsCRP), and von Willebrand factor (vWF) [15], suggesting that PPARγ agonists may reduce endothelial dysfunction in patients with CKD. In keeping with this hypothesis, we demonstrated that patients who received rosiglitazone were more likely to show a decrease in cfDNA levels after 8 weeks than those who received placebo (although absolute differences in cfDNA levels were not statistically significant) and that cfDNA levels correlated to levels of vWF and cfDNA, established markers of endothelial dysfunction [40, 41].

There are several limitations to our study. Despite the use of a high sensitivity cytokine detection kit and an optimized protocol for the detection of cfDNA, levels of cfDNA and several cytokines were at the lower limits of detection, which may have reduced the ability to detect small differences compared to background. Eight-week therapy with rosiglitazone may have been insufficient for meaningful differences in cfDNA levels to develop or the anti-inflammatory benefits of this agent may only become evident in the presence of more overt inflammation where levels of cytokines and cfDNA are orders of magnitude higher [10, 42]. Further prospective studies will be required to answer these questions and to resolve whether PPAR agonists have a therapeutic role in inflammatory states [43–46].

5. Conclusions

Chronic kidney disease is an inflammatory state associated with increased cardiovascular morbidity and mortality. cfDNA levels are elevated in the presence of inflammation, have been proposed as a biomarker for cardiovascular risk and a tool to monitor inflammatory conditions, and have intrinsic proinflammatory properties. The impact of renal impairment on cell-free DNA levels has not previously been systematically studied. The stage of CKD does not influence levels of cfDNA; however, there is a correlation with levels of hsCRP and vWF, but not other inflammatory cytokines associated with endothelial dysfunction. PPARγ agonists may have a role in reducing cfDNA levels. cfDNA levels do not reflect the elevated cardiovascular risk in patients with CKD but may therefore retain their utility as a biomarker for other inflammatory conditions in patients with renal impairment.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors would like to thank Alysia Buckley from the University of Western Australia’s Centre for Microscopy, Characterization and Analysis (CMCA) for assistance with the Luminex 200 system.

References

[1] E. Di Angelantonio, R. Chowdhury, N. Sarwar, T. Aspelund, J. Danesh, and V. Gudnason, "Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality:
prospective population based cohort study,” *The British Medical Journal*, vol. 341, no. 7776, Article ID e4986, 2010.

[2] M. J. Sarnak, A. S. Levey, A. C. Schoolwerth et al., “Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention,” *Circulation*, vol. 108, no. 17, pp. 2154–2169, 2003.

[3] J. Jylhävä, T. Lehtimäki, A. Jula et al., “Circulating cell-free DNA is associated with cardiometabolic risk factors: the Health 2000 Survey,” *Atherosclerosis*, vol. 233, no. 1, pp. 268–271, 2014.

[4] H. Schwarzenbach, D. S. B. Hoon, and K. Pantel, “Cell-free nucleic acids as biomarkers in cancer patients,” *Nature Reviews Cancer*, vol. 11, no. 6, pp. 426–437, 2011.

[5] E. M. Tan, P. H. Schur, R. I. Carr, and H. G. Kunkel, “Deoxyribonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus,” *The Journal of Clinical Investigation*, vol. 45, no. 11, pp. 1732–1740, 1966.

[6] T. W. Chiu, R. Young, L. Y. S. Chan, A. Burd, and D. Y. M. Lo, “Plasma cell-free DNA as an indicator of severity of injury in burn patients,” *Clinical Chemistry and Laboratory Medicine*, vol. 44, no. 1, pp. 13–17, 2006.

[7] Y. M. D. Lo, T. H. Rainer, L. Y. S. Chan, N. M. Hjelm, and R. A. Cocks, “Plasma DNA as a prognostic marker in trauma patients,” *Clinical Chemistry*, vol. 46, no. 3, pp. 319–323, 2000.

[8] T. H. Rainer, L. K. S. Wong, W. Lam et al., “Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke,” *Clinical Chemistry*, vol. 49, no. 4, pp. 562–569, 2003.

[9] T. K. Outinen, T. Kuparinne, J. Jylhävä et al., “Plasma cell-free DNA levels are elevated in acute puumula hantavirus infection,” *PloS ONE*, vol. 7, no. 2, Article ID e31455, 2012.

[10] K. Saukkonen, P. Lakkisto, V. Pettilä et al., “Cell-free plasma DNA as a predictor of outcome in severe sepsis and septic shock,” *Clinical Chemistry*, vol. 54, no. 6, pp. 1000–1007, 2008.

[11] J. Atamaniuk, K. Ruzicka, K. M. Stuhlmeier, A. Karimi, M. Eigner, and M. M. Mueller, “Cell-free plasma DNA: a marker for apoptosis during hemodialysis,” *Clinical Chemistry*, vol. 52, no. 3, pp. 523–526, 2006.

[12] P. Stenvinkel, “Inflammation in end-stage renal disease—a fire that burns within,” *Contributions to Nephrology*, vol. 149, pp. 185–199, 2005.

[13] S.-H. Lin, Y.-F. Lin, S.-W. Kuo, Y.-J. Hsu, and Y.-J. Hung, “Rosiglitazone improves glucose metabolism in non-diabetic uremic patients on CAPD,” *The American Journal of Kidney Diseases*, vol. 42, no. 4, pp. 774–780, 2003.

[14] G. Dogra, A. Irish, D. Chan, and G. Watts, “A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD,” *American Journal of Kidney Diseases*, vol. 49, no. 6, pp. 776–785, 2007.

[15] D. T. Chan, G. F. Watts, A. B. Irish, and G. K. Dogra, “Rosiglitazone does not improve vascular function in subjects with chronic kidney disease,” *Nephrology Dialysis Transplantation*, vol. 26, no. 11, pp. 3543–3549, 2011.

[16] J. Atamaniuk, C. Kopecky, S. Skoupy, M. D. Säemann, and T. Weichhart, “Apoptotic cell-free DNA promotes inflammation in haemodialysis patients,” *Nephrology Dialysis Transplantation*, vol. 27, no. 3, pp. 902–905, 2012.

[17] S. M. Haffner, A. S. Greenberg, W. M. Weston, H. Chen, K. Williams, and M. I. Freed, “Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus,” *Circulation*, vol. 106, no. 6, pp. 679–684, 2002.

[18] H. Ghanim, S. Dhindsa, A. Aljada, A. Chaudhuri, P. Viswanathan, and P. Dandona, “Low-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabetics,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 91, no. 9, pp. 3553–3558, 2006.

[19] K. Esposito, M. Cirotta, D. Merante, and D. Giugliano, “Rosiglitazone cools down inflammation in the metabolic syndrome,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 26, no. 6, pp. 1413–1414, 2006.

[20] E. Linden, W. Cai, J. C. He et al., “Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation,” *Clinical Journal of the American Society of Nephrology*, vol. 3, no. 3, pp. 691–698, 2008.

[21] N. Urosevic, T. J. J. Inglis, J. Grasko, and E. M. Lim, “Evaluation of clinical laboratory methods for plasma cell-free DNA analysis in suspected septicemia,” *Journal of Medical Diagnostic Methods*, vol. 2, article 123, 2013.

[22] A. O. Spiel, J. C. Gilbert, and B. Jilma, “Von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes,” *Circulation*, vol. 117, no. 11, pp. 1449–1459, 2008.

[23] P. M. Ridker, “High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease,” *Circulation*, vol. 103, no. 13, pp. 1813–1818, 2001.

[24] M. Korabecna, S. Opatrna, J. Wirth et al., “Cell-free plasma DNA during peritoneal dialysis and hemodialysis in patients with chronic kidney disease,” *Annals of the New York Academy of Sciences*, vol. 1137, pp. 296–301, 2008.

[25] D. W. Swinkels, E. Wiegnerck, E. A. P. Steegers, and J. B. De Kok, “Effects of blood-processing protocols on cell-free DNA quantification in plasma,” *Clinical Chemistry*, vol. 49, no. 3, pp. 525–526, 2003.

[26] K. Page, T. Powles, M. J. Slade et al., “The importance of careful blood processing in isolation of cell-free DNA,” *Annals of the New York Academy of Sciences*, vol. 1075, pp. 313–317, 2006.

[27] S. Breitbach, S. Tug, and P. Simon, “Circulating cell-free DNA: an up-coming molecular marker in exercise physiology,” *Sports Medicine*, vol. 42, no. 7, pp. 565–586, 2012.

[28] S. H. Hohaus, M. Giachelia, G. Massini et al., “Cell-free circulating DNA in Hodgkin’s and non-Hodgkin’s lymphomas,” *Annals of Oncology*, vol. 20, no. 8, pp. 1408–1413, 2009.

[29] C. Nicolini, C. Ens, T. Cerutti et al., “Elevated level of cell-free plasma DNA is associated with advanced-stage breast cancer and metastasis,” *Clinical Chemistry and Laboratory Medicine*, vol. 51, no. 11, pp. e277–e278, 2013.

[30] K. A. Yoon, S. Park, S. H. Lee, J. H. Kim, and J. S. Lee, “Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls,” *Journal of Molecular Diagnostics*, vol. 11, no. 3, pp. 182–185, 2009.

[31] I. Botezatu, O. Serdyuk, G. Potapova et al., “Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism,” *Clinical Chemistry*, vol. 46, no. 8, pp. 1078–1084, 2000.
[32] G. Dogra, A. Irish, D. Chan, and G. Watts, “Insulin resistance, inflammation, and blood pressure determine vascular dysfunction in CKD,” *American Journal of Kidney Diseases*, vol. 48, no. 6, pp. 926–934, 2006.

[33] G. M. Rubanyi, “The role of endothelium in cardiovascular homeostasis and diseases,” *Journal of Cardiovascular Pharmacology*, vol. 22, supplement 4, pp. S1–S14, 1993.

[34] N. Marx, T. Bourcier, G. K. Sukhova, P. Libby, and J. Plutzky, “PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 19, no. 3, pp. 546–551, 1999.

[35] N. Marx, T. Bourcier, G. K. Sukhova, P. Libby, and J. Plutzky, “PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 19, no. 3, pp. 546–551, 1999.

[36] A. C. Li, K. K. Brown, M. J. Silvestre, T. M. Willson, W. Palinski, and C. K. Glass, “Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice,” *The Journal of Clinical Investigation*, vol. 106, no. 4, pp. 523–531, 2000.

[37] S. K. Vijay, M. Mishra, H. Kumar, and K. Tripathi, “Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes,” *Acta Diabetologica*, vol. 46, no. 1, pp. 27–33, 2009.

[38] S. E. Nissen and K. Wolski, “Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,” *The New England Journal of Medicine*, vol. 356, no. 24, pp. 2457–2471, 2007.

[39] K. W. Mahaffey, G. Hafley, S. Dickerson et al., “Results of a reevaluation of cardiovascular outcomes in the RECORD trial,” *American Heart Journal*, vol. 166, no. 2, pp. 240.e1–249.el, 2013.

[40] P. D. Home, S. J. Pocock, H. Beck-Nielsen et al., “Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial,” *The Lancet*, vol. 373, no. 9681, pp. 2125–2135, 2009.

[41] V. F. Azevedo, J. R. Faria-Neto, A. Stinghen et al., “IL-8 but not other biomarkers of endothelial damage is associated with disease activity in patients with ankylosing spondylitis without treatment with anti-TNF agents,” *Rheumatology International*, vol. 33, no. 7, pp. 1779–1783, 2013.

[42] P. E. Szmitko, C.-H. Wang, R. D. Weisel, J. R. de Almeida, T. J. Anderson, and S. Verma, “New Markers of Inflammation and Endothelial Cell Activation Part I,” *Circulation*, vol. 108, no. 16, pp. 2125–2135, 2003.

[43] R. Huttunen, T. Kuparinne, J. Jylhävä et al., “Fatal outcome in bacteremia is characterized by high plasma cell free DNA concentration and apoptotic DNA fragmentation: a prospective cohort study,” *PLoS ONE*, vol. 6, no. 7, Article ID e21700, 2011.

[44] M. P. Fink, “Peroxisome proliferator-activated receptor-γ ligands: a pluripotent class of pharmacological agents that may prove to be useful for adjuvant treatment of sepsis and multiple organ dysfunction syndrome,” *Critical Care Medicine*, vol. 32, no. 2, pp. 604–605, 2004.

[45] A. K. Boggild, S. Krudsood, S. N. Patel et al., “Use of peroxisome proliferator-activated receptor γ agonists as adjunctive treatment for Plasmodium falciparum malaria: a randomized, double-blind, placebo-controlled trial,” *Clinical Infectious Diseases*, vol. 49, no. 6, pp. 841–849, 2009.

[46] A. M. Siddiqui, X. Cui, R. Wu et al., “The anti-inflammatory effect of curcumin in an experimental model of sepsis is mediated by up-regulation of peroxisome proliferator-activated receptor-γ,” *Critical Care Medicine*, vol. 34, no. 7, pp. 1874–1882, 2006.